FDA Grants Priority Review to Genentech ’s Personalized Medicine Entrectinib

South San Francisco, CA -- February 18, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news